首页 > 最新文献

The Brown University Psychopharmacology Update最新文献

英文 中文
Esketamine monotherapy efficacious in treatment-resistant depression 艾氯胺酮单药治疗难治性抑郁症有效
The Brown University Psychopharmacology Update
Pub Date : 2025-10-10 DOI: 10.1002/pu.31369

Twice-weekly dosing of intranasal esketamine resulted in significant improvement in depressive symptoms compared with placebo in adults with treatment-resistant depression, a 4-week trial has found. Esketamine doses of 56 and 84 mg both outperformed ­placebo in the post-marketing trial. Study results were published online July 2, 2025, in JAMA Psychiatry.

一项为期4周的试验发现，与安慰剂相比，每周两次鼻用艾氯胺酮可显著改善成人难治性抑郁症患者的抑郁症状。在上市后试验中，56毫克和84毫克的艾氯胺酮剂量均优于安慰剂。研究结果于2025年7月2日在线发表在《美国医学会精神病学杂志》上。
{"title":"Esketamine monotherapy efficacious in treatment-resistant depression","authors":"","doi":"10.1002/pu.31369","DOIUrl":"https://doi.org/10.1002/pu.31369","url":null,"abstract":"<p>Twice-weekly dosing of intranasal esketamine resulted in significant improvement in depressive symptoms compared with placebo in adults with treatment-resistant depression, a 4-week trial has found. Esketamine doses of 56 and 84 mg both outperformed ­placebo in the post-marketing trial. Study results were published online July 2, 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 11","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antidepressant discontinuation: Skepticism and science 抗抑郁药停药：怀疑与科学
The Brown University Psychopharmacology Update
Pub Date : 2025-10-10 DOI: 10.1002/pu.31376
Lawrence H. Price M.D.
{"title":"Antidepressant discontinuation: Skepticism and science","authors":"Lawrence H. Price M.D.","doi":"10.1002/pu.31376","DOIUrl":"https://doi.org/10.1002/pu.31376","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 11","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study suggests antipsychotics reduce risk of relapse to catatonia 研究表明抗精神病药物可以降低紧张症复发的风险
The Brown University Psychopharmacology Update
Pub Date : 2025-10-10 DOI: 10.1002/pu.31373
{"title":"Study suggests antipsychotics reduce risk of relapse to catatonia","authors":"","doi":"10.1002/pu.31373","DOIUrl":"https://doi.org/10.1002/pu.31373","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 11","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review finds low rate of symptoms associated with antidepressant discontinuation 回顾发现与抗抑郁药停药相关的症状发生率低
The Brown University Psychopharmacology Update
Pub Date : 2025-10-10 DOI: 10.1002/pu.31368

A systematic review and meta-analysis of 50 randomized controlled trials has found that although antidepressant discontinuation resulted in more symptoms than placebo discontinuation, the between-group difference on average was only just over one symptom. The rate of antidepressant discontinuation symptoms was lower than that reported in earlier reviews. Results of the review and meta-analysis were published online July 9, 2025, in JAMA Psychiatry.

一项对50个随机对照试验的系统回顾和荟萃分析发现，尽管停用抗抑郁药比停用安慰剂导致更多的症状，但组间平均差异仅略高于一种症状。抗抑郁药停药症状的发生率低于早期综述的报道。该综述和荟萃分析的结果于2025年7月9日在线发表在《美国医学会精神病学杂志》上。
{"title":"Review finds low rate of symptoms associated with antidepressant discontinuation","authors":"","doi":"10.1002/pu.31368","DOIUrl":"https://doi.org/10.1002/pu.31368","url":null,"abstract":"<p>A systematic review and meta-analysis of 50 randomized controlled trials has found that although antidepressant discontinuation resulted in more symptoms than placebo discontinuation, the between-group difference on average was only just over one symptom. The rate of antidepressant discontinuation symptoms was lower than that reported in earlier reviews. Results of the review and meta-analysis were published online July 9, 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 11","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lumateperone improves symptoms in unipolar and bipolar depression with mixed features Lumateperone可改善单极和双相抑郁症混合性症状
The Brown University Psychopharmacology Update
Pub Date : 2025-10-10 DOI: 10.1002/pu.31375
{"title":"Lumateperone improves symptoms in unipolar and bipolar depression with mixed features","authors":"","doi":"10.1002/pu.31375","DOIUrl":"https://doi.org/10.1002/pu.31375","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SSRI, SNRI augmentation of clozapine reduces relapse in treatment-resistant schizophrenia SSRI、SNRI增加氯氮平可减少难治性精神分裂症的复发
The Brown University Psychopharmacology Update
Pub Date : 2025-10-10 DOI: 10.1002/pu.31372

An analysis based on data from two national cohort studies has found that augmentation of clozapine treatment with a selective serotonin reuptake inhibitor (SSRI) or serotonin-­norepinephrine reuptake inhibitor (SNRI) reduces risk of relapse in patients with treatment-resistant schizophrenia. Augmentation with other antidepressants did not reduce risk of relapse, and the beneficial effects of SSRIs and SNRIs were observed only at low or standard doses of the antidepressants.

一项基于两项国家队列研究数据的分析发现，选择性5 -羟色胺再摄取抑制剂（SSRI）或5 -羟色胺-去甲肾上腺素再摄取抑制剂（SNRI）增加氯氮平治疗可降低难治性精神分裂症患者复发的风险。与其他抗抑郁药物联合使用并不能降低复发的风险，SSRIs和SNRIs的有益效果仅在低剂量或标准剂量的抗抑郁药物中观察到。
{"title":"SSRI, SNRI augmentation of clozapine reduces relapse in treatment-resistant schizophrenia","authors":"","doi":"10.1002/pu.31372","DOIUrl":"https://doi.org/10.1002/pu.31372","url":null,"abstract":"<p>An analysis based on data from two national cohort studies has found that augmentation of clozapine treatment with a selective serotonin reuptake inhibitor (SSRI) or serotonin-­norepinephrine reuptake inhibitor (SNRI) reduces risk of relapse in patients with treatment-resistant schizophrenia. Augmentation with other antidepressants did not reduce risk of relapse, and the beneficial effects of SSRIs and SNRIs were observed only at low or standard doses of the antidepressants.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term study confirms safety of esketamine for treatment-resistant depression 长期研究证实艾氯胺酮治疗难治性抑郁症的安全性
The Brown University Psychopharmacology Update
Pub Date : 2025-09-09 DOI: 10.1002/pu.31360
{"title":"Long-term study confirms safety of esketamine for treatment-resistant depression","authors":"","doi":"10.1002/pu.31360","DOIUrl":"https://doi.org/10.1002/pu.31360","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 10","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145011998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cohort study finds glucocorticoids increase risk of anxiety, depression 队列研究发现糖皮质激素会增加焦虑、抑郁的风险
The Brown University Psychopharmacology Update
Pub Date : 2025-09-09 DOI: 10.1002/pu.31359

A population-based cohort study using both self-controlled and target trial emulation approaches has reported an association between use of oral glucocorticoids and increased risk of adverse psychiatric outcomes. Use of glucocorticoids was found to be associated with higher risk of depressive, bipolar, and anxiety disorders but did not increase risk of suicidality.

一项基于人群的队列研究使用自我控制和目标试验模拟方法报道了口服糖皮质激素与不良精神结局风险增加之间的关联。研究发现，糖皮质激素的使用与抑郁症、双相情感障碍和焦虑症的高风险相关，但不会增加自杀的风险。
{"title":"Cohort study finds glucocorticoids increase risk of anxiety, depression","authors":"","doi":"10.1002/pu.31359","DOIUrl":"https://doi.org/10.1002/pu.31359","url":null,"abstract":"<p>A population-based cohort study using both self-controlled and target trial emulation approaches has reported an association between use of oral glucocorticoids and increased risk of adverse psychiatric outcomes. Use of glucocorticoids was found to be associated with higher risk of depressive, bipolar, and anxiety disorders but did not increase risk of suicidality.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second-line strategies more effective than dose optimization in depression treatment 二线策略治疗抑郁症比剂量优化更有效
The Brown University Psychopharmacology Update
Pub Date : 2025-09-09 DOI: 10.1002/pu.31358

Alternative second-line treatments for major depressive disorder led to higher response and remission rates in comparison to commonly used dose optimization in a randomized trial. The combination of a selective serotonin reuptake inhibitor (SSRI) and psychotherapy resulted in the lowest prevalence of adverse events among the studied second-line strategies.

在一项随机试验中，与常用的剂量优化相比，替代二线治疗对重度抑郁症的疗效和缓解率更高。选择性5 -羟色胺再摄取抑制剂（SSRI）和心理治疗联合使用在二线治疗策略中不良事件发生率最低。
{"title":"Second-line strategies more effective than dose optimization in depression treatment","authors":"","doi":"10.1002/pu.31358","DOIUrl":"https://doi.org/10.1002/pu.31358","url":null,"abstract":"<p>Alternative second-line treatments for major depressive disorder led to higher response and remission rates in comparison to commonly used dose optimization in a randomized trial. The combination of a selective serotonin reuptake inhibitor (SSRI) and psychotherapy resulted in the lowest prevalence of adverse events among the studied second-line strategies.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 10","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide shows favorable safety profile in patients receiving clozapine 西马鲁肽在接受氯氮平治疗的患者中显示出良好的安全性
The Brown University Psychopharmacology Update
Pub Date : 2025-09-09 DOI: 10.1002/pu.31361
{"title":"Semaglutide shows favorable safety profile in patients receiving clozapine","authors":"","doi":"10.1002/pu.31361","DOIUrl":"https://doi.org/10.1002/pu.31361","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
The Brown University Psychopharmacology Update
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1